STAT5A and chronic myelogenous leukemia, BCR-ABL1 positive: Thus, CML is treated with a variety of tyrosine kinase inhibitors (TKIs) specific for the ABL1 kinase, from the first generation imatinib to the third generation ponatinib that targets the imatinib-resistant T315I variant, which all significantly reduce STAT5 activation [3].